What is the main topic?

The article discusses the Diabetic Retinopathy Market, its trends, growth drivers, and forecasts till 2027.

Who are the major players?

Major players include Novartis AG, Regeneron Pharmaceuticals, and Bayer Healthcare.

What drives market growth?

Increasing diabetes incidence and new treatment approvals drive market growth.

Editorial & Advertiser disclosure

Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Home > Research Reports > Diabetic Retinopathy Market Outlook Till, 2027 : Coherent Market Insights

Research Reports

Diabetic Retinopathy Market Outlook Till, 2027 : Coherent Market Insights

Published by Coherent Market Insights

Posted on September 27, 2021

4 min read

Last updated: February 2, 2026

Illustration of data recovery and backup systems related to disaster recovery - Global Banking & Finance Review — An illustration showcasing advanced data recovery solutions, emphasizing the importance of robust backup systems for businesses to quickly restore operations after disasters. Relevant to technology and finance sectors.

Diabetic Retinopathy Market Outlook and Trends Till 2027

Diabetic Retinopathy Market report includes historic data, present market trends, environment, technological innovation, upcoming technologies and the technical progress in the related industry. Diabetic Retinopathy Market offers complete, proficient report delivering market research data that is relevant for new market entrants or set up players. Key strategies of the companies operating in the market and their impact analysis have been included in the report.

Diabetic retinopathy is one of the complications of diabetes, in which blood vessels in the retina gets damaged due to high blood glucose level. Retina is the light sensitive inner lining at the back of the eye. Diabetic retinopathy mostly affects both the eyes. As disease condition progresses, diabetic retinopathy symptoms including fluctuating vision, blurred vision, impaired color vision or sometimes dark and empty areas in vision leads to vision loss. The line of treatment for diabetic retinopathy depending on the disease condition of the patient, may require laser surgery, intraocular injections, and anti (VEFG) vascular endothelial growth factor therapy.

Global Diabetic Retinopathy – Market Dynamics

Increasing incidence of diabetes along with increasing cases of blindness due to diabetes are expected to drive the diabetic retinopathy market growth. According to the International Diabetic Federation report, 2017, around 425 million adults of age group 20 to 79 years are suffering from diabetes. According to the International Agency for the Prevention of Blindness, 2016, one in three people having diabetes have high chances of getting affected by diabetic retinopathy. Moreover, according to the article published in The Lancet, 2018, the annual incidence of diabetic retinopathy ranges from 2.2% to 12.7%, globally.

Moreover, several launches and approvals of new diabetic retinopathy medications are expected to boost growth of the diabetic retinopathy market over the forecast period. For instance, in May 2019, Regeneron Pharmaceutical received the U.S. Food and Drug Administration (FDA) approval for EYLEA, an aflibercept injection for diabetes retinopathy. EYLEA is the only vascular endothelial growth factor (VEGF) inhibitor approved in two dosing options for diabetes retinopathy, allowing doctors to customize treatment as per patient need.

Major Key Players are: Novartis AG, Regeneron Pharmaceuticals, Bayer Healthcare, Actavis Plc, Alimera Science, Pfizer Inc., Hoffmann-La Roche Ltd, Abbott Laboratories Ltd, Sirnaomics, Glycadia pharmaceuticals, Boehringer Ingelheim, Therapeutics Inc, Ampio pharmaceuticals, Lupin ltd, and others.

Intent of the Diabetic Retinopathy Market Research Study:

Project remarkable Diabetic Retinopathy market sections in regards to 5 key areas, mainly in the above all countries.

To re-estimate possibilities for stakeholders by recognizing high-extension elements of the market accordingly.

To determine and forecast the Diabetic Retinopathy client involvement solutions market. It is based on the role, installation type, Diabetic Retinopathy business dimensions, vertical and regions in 2018 to 2026. It also analyze different large-scale and small-scale economic variables which affect the market development.

Diabetic Retinopathy extensive information about important elements such as drivers, restraints, opportunities, and challenges affecting the development of the market.

To scrutinize every Diabetic Retinopathy sub-market connected to discrete development liabilities, expectations and growth.

To observe and inspect Diabetic Retinopathy competitive achievement including combinations and assets, contracts and agreements, joint ventures, Diabetic Retinopathy partnerships, and judicious positions from the client participation solutions market.

Reasons to Purchase this Report

Current and future of global Diabetic Retinopathy market outlook in the developed and emerging markets

The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.

Regions/countries that are expected to witness the fastest growth rates during the forecast period

The latest developments, market shares, and strategies that are employed by the major market players

Contact US:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

Diabetic Retinopathy Market Outlook Till, 2027 : Coherent Market Insights

Quick Summary

Diabetic Retinopathy Market Outlook and Trends Till 2027

Key Takeaways

Frequently Asked Questions about Diabetic Retinopathy Market Outlook Till, 2027 : Coherent Market Insights